PRESS RELEASE published on 05/04/2023 at 12:30, 3 years 1 month ago Moderna Reports First Quarter 2023 Financial Results and Provides Business Updates
PRESS RELEASE published on 05/03/2023 at 22:05, 3 years 1 month ago Moderna Announces Phase 1/2 Data on mRNA-3927, an Investigational mRNA Therapy for Propionic Acidemia (PA) to be Presented at the 2023 ASGCT Annual Meeting
PRESS RELEASE published on 05/02/2023 at 23:15, 3 years 1 month ago Moderna Announces Establishment of an Enterprise Solutions Hub and Commercial Operations in The Philippines
PRESS RELEASE published on 04/20/2023 at 22:05, 3 years 2 months ago Moderna to Report First Quarter 2023 Financial Results on Thursday, May 4, 2023
PRESS RELEASE published on 04/20/2023 at 13:30, 3 years 2 months ago Moderna and IBM to Explore Quantum Computing and Generative AI for mRNA Science
PRESS RELEASE published on 04/16/2023 at 17:00, 3 years 2 months ago Moderna and Merck Announce mRNA-4157 (V940), an Investigational Individualized Neoantigen Therapy, in Combination with KEYTRUDA(R) (Pembrolizumab), Demonstrated Superior Recurrence-Free Survival in Patients with High-Risk Stage III/IV Melanoma Following C
PRESS RELEASE published on 04/11/2023 at 13:00, 3 years 2 months ago Moderna Announces Clinical and Program Updates at 4th Vaccines Day
PRESS RELEASE published on 04/06/2023 at 23:00, 3 years 2 months ago MRNA-4157/V940, an Investigational Personalized MRNA Cancer Vaccine, in Combination With Keytruda(R) (Pembrolizumab), Receives Prime Scheme Designation From the European Medicines Agency for Adjuvant Treatment of Patients With High-Risk Stage III/IV Melan
PRESS RELEASE published on 03/30/2023 at 13:00, 3 years 2 months ago Moderna Finalizes Agreement with the Government of the Republic of Kenya to Establish an mRNA Manufacturing Facility
PRESS RELEASE published on 03/24/2023 at 12:30, 3 years 3 months ago Moderna to Host Fourth Annual Virtual Vaccines Day on April 11, 2023
Published on 06/27/2026 at 16:50, 1 day 8 hours ago Redwood AI Announces Definitive Agreement with Quantum.IQ and Expands into Quantum Resistant Cyber Security
Published on 06/27/2026 at 01:40, 1 day 23 hours ago Polaris Renewable Energy Announces Results of Director Elections at Annual and Special Meeting
Published on 06/27/2026 at 00:00, 2 days ago Onco-Innovations Initiates Three-Species Hepatocyte and Microsome Metabolism Studies for ONC010
Published on 06/26/2026 at 23:00, 2 days 1 hour ago Canadian North Resources Inc. Announces Results of 2026 Annual General and Special Shareholders Meeting
Published on 06/26/2026 at 22:50, 2 days 2 hours ago Banyan Gold Files Technical Report for AurMac Project, Yukon, Canada
Published on 06/28/2026 at 20:00, 4 hours 59 minutes ago CPI Property Group – Successful Hybrid Tender and New Issue
Published on 06/28/2026 at 19:45, 5 hours 14 minutes ago PSP Swiss Property, Invitation Conference Call
Published on 06/28/2026 at 17:26, 7 hours 33 minutes ago EQS-Adhoc: Correction of a release from 24/06/2026, 20:54 CET/CEST - Branicks Group AG sets out timetable for the publication of its 2025 annual and consolidated financial statements
Published on 06/27/2026 at 00:05, 2 days ago EAN Congress: Hearing aid use linked to 23% lower dementia risk in people with both epilepsy and hearing loss
Published on 06/27/2026 at 00:04, 2 days ago Persistent and Nagarro sign Business Combination Agreement to form the Persistent - Nagarro Group, a global leader in AI-led digital engineering
